FDA decision: Rusfertide by Protagonist Therapeutics (in 2026)
FDA decision: Rusfertide by Protagonist Therapeutics (in 2026) Live odds across 1 market: a full approval or an accelerated approval at 100¢. Not financial advi
Resolved
- a full approval or an accelerated approval: Yes 100¢ (kalshi)
TRADING OPEN
8sFDA decision: Rusfertide by Protagonist Therapeutics (in 2026)
Resolved
Total Volume
$2.1K
+$0 (24h)
Active Markets
1
Across 1 platforms
Frontrunner
100¢
a full approval or an accelerated approval
Biggest Mover 24h
+8¢
a full approval or an accelerated approval
Arb Opportunities
0
None detected
All Markets
Implied Probability
Consensus across platformsEvent Info
Whale Activity
Loading...